Cannabidiol

Generic Name: Cannabidiol

Brand Names: Epidiolex, Sativex, Epidyolex

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₃₀O_₂

CAS Number: 13956-29-1

Unique Ingredient Identifier: 19GBJ60SN5

Background: Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical implications are currently being investig...

Indication: When used in combination with delta-9-tetrahydrocannabinol as the product Sativex, cannabidiol was given a standard marketing authorization (ie. a Notice of Compliance (NOC)) by Health Canada for the following indications:
...

Associated Conditions: Multiple Sclerosis, Seizures, Severe Pain, Moderate Pain

Associated Therapies: -

Clinical Trials

Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors

Early Phase 1

Withdrawn

Conditions: Chemotherapy-Induced Peripheral Neuropathy
Breast Carcinoma
Colon Carcinoma

Interventions: Drug: Placebo Administration
Drug: Cannabidiol
Other: Questionnaire Administration
Drug: Delta-8-Tetrahydrocannabinol

First Posted Date: 2023-01-05

Last Posted Date: 2024-08-09

Lead Sponsor: City of Hope Medical Center

Registration Number: NCT05672342

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Evaluation of the Efficacy of CANNABIDIOL on the Pruritus in Children With Hereditary Epidermolysis Bullosa

Phase 2

Completed

Conditions: Hereditary Epidermolysis Bullosa

Interventions: Drug: Cannabidiol

First Posted Date: 2022-12-15

Last Posted Date: 2024-01-24

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 10

Registration Number: NCT05651607

Locations: 🇫🇷
Hôpital Necker Enfants Malades, Paris, France

Investigating the Effects of Cannabidiol on Social Anxiety Disorder

Phase 4

Not yet recruiting

Conditions: Phobia, Social

Interventions: Drug: Placebo
Drug: Cannabidiol

First Posted Date: 2022-12-13

Last Posted Date: 2024-08-22

Lead Sponsor: Massachusetts Institute of Technology

Target Recruit Count: 50

Registration Number: NCT05649059

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Massachusetts Institute of Technology, Cambridge, Massachusetts, United States

Effect of Local Cannabidiol on Clinical and Inflammatory Outcomes in Periodontal Maintenance Patients.

Phase 1

Withdrawn

Conditions: Periodontitis, Adult
Inflammation Gum

Interventions: Drug: cannabidiol
Device: floss
Device: proxabrush

First Posted Date: 2022-12-12

Last Posted Date: 2023-12-04

Lead Sponsor: University of Nebraska

Registration Number: NCT05646459

Cannabinoids and Traumatic Brain Injury: A Randomized, Placebo Controlled Trial

Phase 2

Recruiting

Conditions: Brain Injuries, Traumatic

Interventions: Drug: Placebo
Drug: Cannabidiol

First Posted Date: 2022-11-30

Last Posted Date: 2024-01-10

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 120

Registration Number: NCT05632627

Locations: 🇺🇸
University of Colorado Anschutz, Aurora, Colorado, United States

Alcohol Use Disorder and Cannabidiol

Phase 2

Recruiting

Conditions: Alcohol Use Disorder

Interventions: Drug: Placebo
Drug: Cannabidiol

First Posted Date: 2022-11-14

Last Posted Date: 2024-09-30

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 180

Registration Number: NCT05613608

Locations: 🇺🇸
University of Colorado Anschutz, Aurora, Colorado, United States

Cannabidiol as a Treatment for Social Anxiety Disorder (R61)

Phase 2

Recruiting

Conditions: Social Anxiety Disorder

Interventions: Drug: Placebo
Drug: Cannabidiol

First Posted Date: 2022-10-07

Last Posted Date: 2024-10-03

Lead Sponsor: NYU Langone Health

Target Recruit Count: 60

Registration Number: NCT05571592

Locations: 🇺🇸
NYU Langone Health, New York, New York, United States

Effects of Cannabidiol and Tetrahydrocannabinol on Microbiome and Neuroinflammation in HIV

Phase 2

Recruiting

Conditions: Cannabis
THC
HIV
Neuroinflammatory Disease
Neuroinflammatory Response
Microbiome

Interventions: Drug: THC
Drug: CBD

First Posted Date: 2022-08-25

Last Posted Date: 2024-11-14

Lead Sponsor: University of California, San Diego

Target Recruit Count: 90

Registration Number: NCT05514899

Locations: 🇺🇸
HIV Neurobehavioral Research Program (HNRP), San Diego, California, United States

Assessing the Impact of Cannabidiol for Anxiety and Depression in Bipolar Disorder

Phase 2

Recruiting

Conditions: Bipolar Disorder

Interventions: Drug: Cannabidiol

First Posted Date: 2022-07-14

Last Posted Date: 2024-03-08

Lead Sponsor: Mclean Hospital

Target Recruit Count: 25

Registration Number: NCT05457465

Locations: 🇺🇸
McLean Hospital, Belmont, Massachusetts, United States

Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy

Phase 2

Completed

Conditions: Chemotherapy-Induced Peripheral Neuropathy
Malignant Solid Neoplasm

Interventions: Drug: Cannabidiol
Drug: Placebo Administration
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2022-05-24

Last Posted Date: 2024-04-26

Lead Sponsor: Mayo Clinic

Target Recruit Count: 30

Registration Number: NCT05388058

Locations: 🇺🇸
Fairview Range Medical Center, Hibbing, Minnesota, United States
🇺🇸
Mayo Clinic Health System Albert Lea, Albert Lea, Minnesota, United States
🇺🇸
Mayo Clinic Health System Mankato, Mankato, Minnesota, United States

and more 6 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy